Valuation: Roche Holding AG

Capitalization 255B 326B 279B 242B 448B 31,184B 452B 3,049B 1,184B 14,818B 1,224B 1,198B 51,577B P/E ratio 2026 *
16.9x
P/E ratio 2027 * 15.8x
Enterprise value 266B 340B 291B 252B 466B 32,471B 470B 3,175B 1,233B 15,430B 1,274B 1,247B 53,706B EV / Sales 2026 *
4.24x
EV / Sales 2027 * 3.95x
Free-Float
88.75%
Yield 2026 *
3.13%
Yield 2027 * 3.21%
1 day+3.52%
1 week-0.94%
Current month-0.97%
1 month-0.88%
3 months-12.42%
6 months+10.21%
Current year-3.93%
1 week 313
Extreme 313
323.2
1 month 312
Extreme 312
326.7
Current year 291
Extreme 291
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
+3.46%-0.94%+23.89%+10.73% 326B
-0.89%+3.26%+40.69%+131.73% 898B
+0.16%+3.73%+57.69%+43.55% 556B
+1.09%+3.98%+18.78%+43.23% 372B
+0.68%+3.66%+36.38%+15.27% 287B
+0.98%+3.81%+30.26%+27.24% 285B
-0.04%+0.99%+54.36%-3.18% 280B
+0.91%+1.25%-30.88%-49.10% 207B
-0.07%+2.17%+28.20%+44.34% 181B
-0.74%-1.49%+34.23%+68.94% 164B
Average +0.73%+1.74%+29.36%+33.27% 355.64B
Weighted average by Cap. +0.83%+2.19%+34.30%+51.31%

Financials

2026 *2027 *
Net sales 62.75B 80.11B 68.63B 59.42B 110B 7,659B 111B 749B 291B 3,640B 301B 294B 12,668B 65.33B 83.4B 71.45B 61.87B 115B 7,975B 115B 780B 303B 3,789B 313B 306B 13,190B
Net income 14.79B 18.88B 16.18B 14.01B 25.93B 1,805B 26.14B 177B 68.56B 858B 70.86B 69.35B 2,986B 15.8B 20.18B 17.28B 14.97B 27.71B 1,929B 27.93B 189B 73.26B 917B 75.72B 74.1B 3,191B
Net Debt 10.54B 13.46B 11.53B 9.98B 18.49B 1,287B 18.63B 126B 48.88B 612B 50.51B 49.44B 2,129B 2.71B 3.46B 2.97B 2.57B 4.76B 331B 4.8B 32.39B 12.58B 157B 13B 12.72B 548B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
08/05/26 315.30 CHF -0.94% 590,249
13/05/26 320.00 CHF -0.47% 611,255
12/05/26 321.50 CHF +0.66% 654,692
11/05/26 319.40 CHF +1.30% 724,136
08/05/26 315.30 CHF -0.94% 590,249
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
320.00CHF
Average target price
360.76CHF
Spread / Average Target
+12.74%

Quarterly revenue - Rate of surprise